The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study (Q35561464)

From Wikidata

Jump to navigation Jump to search

scientific article published on 12 February 2015

Language	Label	Description	Also known as
English	The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study	scientific article published on 12 February 2015

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

0 references

renal cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic renal cell carcinoma

1 reference

based on heuristic

inferred from title

Georg A. Bjarnason

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681967 AND SRC:MED&resulttype=core&format=json

2 June 2020

Martin Smoragiewicz

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681967 AND SRC:MED&resulttype=core&format=json

2 June 2020

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681967 AND SRC:MED&resulttype=core&format=json

2 June 2020

Ravindran Kanesvaran

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681967 AND SRC:MED&resulttype=core&format=json

2 June 2020

Ulka Vaishampayan

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681967 AND SRC:MED&resulttype=core&format=json

2 June 2020

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681967 AND SRC:MED&resulttype=core&format=json

2 June 2020

Toni K Choueiri

19

object named as

Toni K Choueiri

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681967 AND SRC:MED&resulttype=core&format=json

2 June 2020

author name string

Jenny J Ko

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681967 AND SRC:MED&resulttype=core&format=json

2 June 2020

Wanling Xie

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681967 AND SRC:MED&resulttype=core&format=json

2 June 2020

Nils Kroeger

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681967 AND SRC:MED&resulttype=core&format=json

2 June 2020

Jae-Lyun Lee

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681967 AND SRC:MED&resulttype=core&format=json

2 June 2020

Brian I Rini

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681967 AND SRC:MED&resulttype=core&format=json

2 June 2020

Jennifer J Knox

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681967 AND SRC:MED&resulttype=core&format=json

2 June 2020

Sandy Srinivas

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681967 AND SRC:MED&resulttype=core&format=json

2 June 2020

Sumanta K Pal

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681967 AND SRC:MED&resulttype=core&format=json

2 June 2020

Takeshi Yuasa

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681967 AND SRC:MED&resulttype=core&format=json

2 June 2020

Lori Wood

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681967 AND SRC:MED&resulttype=core&format=json

2 June 2020

D Scott Ernst

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681967 AND SRC:MED&resulttype=core&format=json

2 June 2020

Neeraj Agarwal

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681967 AND SRC:MED&resulttype=core&format=json

2 June 2020

Daniel Y C Heng

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681967 AND SRC:MED&resulttype=core&format=json

2 June 2020

publication date

12 February 2015

1 reference

Europe PubMed Central

PubMed publication ID

8 August 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681967 AND SRC:MED&resulttype=core&format=json

2 June 2020

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681967 AND SRC:MED&resulttype=core&format=json

2 June 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681967 AND SRC:MED&resulttype=core&format=json

2 June 2020

293-300

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681967 AND SRC:MED&resulttype=core&format=json

2 June 2020

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)71222-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)71222-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)71222-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)71222-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: results from the Danish Renal Cancer Group (DARENCA) study-2.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)71222-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)71222-7

7 January 2021

based on heuristic

inferred from DOI database lookup

External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)71222-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)71222-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)71222-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Regression modelling strategies for improved prognostic prediction

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)71222-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluating the yield of medical tests

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)71222-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)71222-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)71222-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)71222-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)71222-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)71222-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)71222-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)71222-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000-2008).

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)71222-7

7 January 2021

based on heuristic

inferred from DOI database lookup

'Would you like to talk about your future treatment options'? Discussing the transition from curative cancer treatment to palliative care

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)71222-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Pazopanib versus sunitinib in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)71222-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)71222-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)71222-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)71222-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Erythrocyte sedimentation rate kinetics as a marker of treatment response and predictor of prognosis in Chinese metastatic renal cell carcinoma patients treated with sorafenib

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)71222-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)71222-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)71222-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)71222-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)71222-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(14)71222-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(14)71222-7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681967 AND SRC:MED&resulttype=core&format=json

2 June 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25681967 AND SRC:MED&resulttype=core&format=json

2 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35561464&oldid=1579516622"